Variability in Phelan-McDermid Syndrome in a Cohort of 210 Individuals

Other authors

Institut Català de la Salut

[Nevado J, García-Miñaúr S, Palomares-Bralo M, Vallespín E] Instituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz, Madrid, Spain. CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain. ITHACA-European Reference Network, Hospital La Paz, Madrid, Spain. [Guillén-Navarro E] Hospital Virgen de la Arrixaca, Murcia, Spain. [Rosell J] Hospital Son Espases, Palma de Mallorca, Spain. [del Campo M] Vall d’Hebron Hospital Universitari, Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2023-01-12T13:07:42Z

2023-01-12T13:07:42Z

2022-04-12



Abstract

Phelan-McDermid syndrome; Intellectual disabilities; Subtelomeric deletion syndrome


Síndrome de Phelan-McDermid; Discapacidades intelectuales; Síndrome de deleción subtelomérica


Síndrome de Phelan-McDermid; Discapacitats intel·lectuals; Síndrome de deleció subtelomèrica


Phelan-McDermid syndrome (PMS, OMIM# 606232) results from either different rearrangements at the distal region of the long arm of chromosome 22 (22q13.3) or pathogenic sequence variants in the SHANK3 gene. SHANK3 codes for a structural protein that plays a central role in the formation of the postsynaptic terminals and the maintenance of synaptic structures. Clinically, patients with PMS often present with global developmental delay, absent or severely delayed speech, neonatal hypotonia, minor dysmorphic features, and autism spectrum disorders (ASD), among other findings. Here, we describe a cohort of 210 patients with genetically confirmed PMS. We observed multiple variant types, including a significant number of small deletions (<0.5 Mb, 64/189) and SHANK3 sequence variants (21 cases). We also detected multiple types of rearrangements among microdeletion cases, including a significant number with post-zygotic mosaicism (9.0%, 17/189), ring chromosome 22 (10.6%, 20/189), unbalanced translocations (de novo or inherited, 6.4%), and additional rearrangements at 22q13 (6.3%, 12/189) as well as other copy number variations in other chromosomes, unrelated to 22q deletions (14.8%, 28/189). We compared the clinical and genetic characteristics among patients with different sizes of deletions and with SHANK3 variants. Our findings suggest that SHANK3 plays an important role in this syndrome but is probably not uniquely responsible for all the spectrum features in PMS. We emphasize that only an adequate combination of different molecular and cytogenetic approaches allows an accurate genetic diagnosis in PMS patients. Thus, a diagnostic algorithm is proposed.


REDES/FIBHULP08. FIBHULP PI: 2735. FIBHULP Auchan Reserch Project. FIBHULP. Raregenomics (B2017/BMD-3721).

Document Type

Article


Published version

Language

English

Publisher

Frontiers Media

Related items

Frontiers in Genetics;13

https://doi.org/10.3389/fgene.2022.652454

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)